Compare Recursion Pharmaceuticals Inc (RXRX) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while iShares Broad USD Investment Grade Corporate Bond trades at $49.89. The key difference: Recursion Pharmaceuticals Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| RXRX | USIG | |
|---|---|---|
Market Cap | $1.86B | — |
Sector | Health | Fixed Income |
52-Week High | $6.79 | $52.69 |
52-Week Low | $2.84 | $49.89 |
Enterprise Value | $1.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
USIG trades at $49.96, down 0.08% on the day, with technical indicators showing a bearish trend. Recent corporate actions include scheduled dividend payments in 2026. Institutional interest is evident from new stakes by Blue Edge Capital LLC and increased holdings by Bank of New York Mellon Corp, as reported by Defense World and Business Wire in July and August 2026.
The outlook remains cautious due to bearish technical signals and lack of recent fundamental data. Investment opportunities hinge on future financial disclosures and institutional support, while risks include market volatility and reliance on upcoming earnings for valuation clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
